ABBVAbbVie Inc.SEC EDGAR
Use with Claude or ChatGPT
  • Overview
  • Income statement
  • Balance sheet
  • Cash flow
  • Earnings

AbbVie Inc. (ABBV) Earnings history

6 quarters held0/8 transcripts analyzed2/30 figures attested
Ask your agent: get_earnings
PeriodRevenueYoYNet incomeEPS (dil.)Filed
Q3 2026$17.4B+10.3%$4.2B$2.37Oct 30, 2026
LATESTEarnings filing (8-K)10-QFiled Oct 30, 2026, 7:51 AM ET
Earnings call · Oct 30, 2026
Q3 FY26YoY9M FY26
Revenue$17.4B1+10.3%$49.4B
Net income$4.2B+2167.7%–
Op income$6.3B+229.1%–
EPS (dil.)$2.37+2270.0%–
EPS (basic)–––
Gross margin75.4%–
Op margin36.0%–
Net margin24.2%+23.1pp
  1. [1] “Net revenues | $ | 17,404” view source

Guidance & outlook

Management guidance

Q3 2026

fy_current

eps_diluted
$13.95—$13.99

Special items & operational metrics

Operational metrics

Q3 2026

LLM-extracted from the earnings release; unverified.

Skyrizi Revenue
5776.0M
+22.7% YoY
dollars
Rinvoq Revenue
2706.0M
+23.9% YoY
dollars
Q2 2026$17.0B+10.2%$3.6B$2.03Jul 31, 2026
10-QFiled Jul 31, 2026, 7:51 AM ET
Earnings call · Jul 31, 2026
Q2 FY26YoY6M FY26
Revenue$17.0B1+10.2%$32.0B
Net income$3.6B––
Op income$6.4B––
EPS (dil.)$2.03+290.4%$2.42
EPS (basic)–––
Net margin21.3%–
  1. [1] “Net Revenues (in millions) Total Reported $16,990” view source
Q1 2026$15.0B+12.4%$697.0M–Apr 29, 2026
Earnings filing (8-K)10-QFiled Apr 29, 2026, 7:50 AM ET
Earnings call · Apr 29, 2026
Q1 FY26YoY
Revenue$15.0B+12.4%
Net income$697.0M-45.8%
Op income$4.0B+6.9%
EPS (dil.)––
EPS (basic)––
Gross margin71.9%–
Op margin26.6%–
Net margin4.7%-5.0pp
Q3 2025$15.8B+9.1%$186.0M$0.10Oct 31, 2025
Earnings filing (8-K)
Q3 FY25YoY9M FY25
Revenue$15.8B+9.1%$44.5B
Net income$186.0M-87.9%$2.4B
Op income$1.9B-50.3%$10.5B
EPS (dil.)$0.10-88.6%$1.34
EPS (basic)–––
Gross margin66.4%–
Op margin12.1%-14.4pp
Net margin1.2%-9.6pp
Q2 2025$15.4B+6.6%$938.0M$0.52Jul 31, 2025
Earnings filing (8-K)
Q2 FY25YoY6M FY25
Revenue$15.4B+6.6%$28.8B
Net income$938.0M-31.5%$2.2B
Op income$4.9B+22.4%$8.6B
EPS (dil.)$0.52-32.5%$1.24
EPS (basic)–––
Gross margin71.8%–
Op margin31.7%–
Net margin6.1%-3.4pp
Q1 2025$13.3B+8.4%$1.3B$0.72Apr 25, 2025
Earnings filing (8-K)
Q1 FY25YoY
Revenue$13.3B+8.4%
Net income$1.3B-6.1%
Op income$3.7B+33.4%
EPS (dil.)$0.72-6.5%
EPS (basic)$0.72-6.5%
Gross margin70.0%–
Op margin28.0%–
Net margin9.6%-1.5pp

IR event calendar

This company's IR event calendar has not been harvested yet — an empty result here does NOT mean the company has no IR events.

Filing coverage

84 filings indexed · 63,762 XBRL facts
FilingDatePeriodSectionsTables
10-Q2026-11-03–3272
8-K2026-11-02–10
8-K2026-10-30Q3 202680
8-K2026-10-15–10
8-K2026-10-05Q3 202650
8-K2026-09-03–30
8-K2026-08-18–20
8-K2026-08-05–20
10-Q2026-08-03–3158
8-K2026-07-31–80

Showing the latest 10 of 84 — the full set is in the API.

Related Research

Analysis

The $15 Billion Earnings Illusion Inside AbbVie's 10-K

Analysis

Boston Scientific Hit a ROIC Inflection — Then Bet $14.5B on Penumbra

Analysis

Four Forces Are Manufacturing Regeneron's EPS Growth as Operations Decline